All Oncology News

To gain insight into the integration of olaparib into clinical practice, OncLive interviewed Ursula A. Matulonis, MD, medical director of gynecologic oncology at Dana-Farber Cancer Institute.

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer specialists and primary care physicians deliver high quality of care to patients with localized disease.

Adverse events among patients with metastatic colorectal cancer who responded best to regorafenib in the phase III CORRECT trial were "broadly similar" to the overall study population.

The CMS announced the launch of an Oncology Care Model that contains goals and incentives for practitioners in cancer care.

The FDA has granted approval to lenvatinib (Lenvima) as a treatment for patients with progressive, radioactive iodine-refractory differentiated thyroid cancer.

The COA has weighed in on a new system of higher value performance for oncologists, saying it is a step in the right direction but needs to be supported by broader reforms.

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy talimogene laherparepvec as a treatment for patients with metastatic melanoma.

The Myriad myPath Melanoma molecular diagnostic test was effective in helping practitioners differentiate between benign and malignant melanocytic lesions, according to results from a prospective study.

The FDA has granted an orphan drug designation to Reolysin for the treatment of patients with ovarian cancer.

The proteasome inhibitor ixazomib met its primary endpoint of improving progression-free survival at a prespecified interim analysis of a phase III trial of patients with relapsed/refractory multiple myeloma.

With a deadline of April 14, the FDA will soon make its final approval decision on the oral multikinase inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

For further insight on the significance of palbociclib's approval, OncLive sat down with the lead investigator of PALOMA-1, Richard Finn, MD, from the Jonsson Comprehensive Cancer Center at UCLA.

OncLive today welcomes Rutgers Cancer Institute of New Jersey as a partner in promoting awareness of the most recent advances in cancer care through OncLive's Strategic Alliance Partnership program

The American Board of Internal Medicine (ABIM) is making substantial changes to its Maintenance of Certification Program (MOC) for internists and subspecialists.

Medicare will immediately cover lung cancer screening with low-dose computed tomography for high-risk individuals, including current and former smokers.

The risk of death was significantly reduced for patients with BRAFV600E/K mutation-positive metastatic melanoma treated with dabrafenib (Tafinlar) and trametinib (Mekinist) compared with dabrafenib alone.

For insight on the evolving role of PARP inhibitors in the treatment of ovarian cancer, OncLive interviewed Donna McNamara, MD, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC).

US-based global pharmaceuticals giant Pfizer Inc. will acquire Hospira Inc., a leading maker of sterile injectable drugs and infusion technologies, in a deal valued at $17 billion including debt.

A phase III study of obinutuzumab in indolent non-Hodgkin lymphoma has been stopped early after a positive interim analysis.

Biopsy-based cell cycle progression gene expression testing can aid in the stratification of patients with localized prostate cancer based on disease aggressiveness.

OncLive® and Fox Chase Cancer Center, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center that is part of the Temple University Health System in Philadelphia, announced that they have joined forces to raise awareness of significant oncology research and clinical practice news through OncLive's Strategic Alliance Partnership program.

The FDA has granted an accelerated approval to palbociclib as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

The FDA has granted a priority review to trabectedin (Yondelis) to treat patients with advanced soft tissue sarcoma.

The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer that has progressed during or after platinum-based chemotherapy, as well as a targeted therapy for patients with EGFR- or ALK-positive tumors.

A Spanish foundation has awarded a major scientific prize to Yale researcher Joseph Schlessinger and two colleagues in recognition of their work leading to the first personalized treatments for cancer. The 2015 Frontiers of Knowledge Award in Biomedicine from the Madrid-based BBVA Foundation includes a €400,000 cash priz

OncLive® welcomes the University of Chicago Medicine Comprehensive Cancer Center as a partner in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program.

The 'precision medicine initiative' proposed by President Barack Obama will require an initial investment of $215 million and consent from 1 million volunteers, with the goal of discovering potential cures for patients with cancer.

The FDA has expanded the approval of ibrutinib for the treatment of patients with Waldenström’s macroglobulinemia, according to a press release.

An increased understanding of tumor immunology has led to seven new melanoma drug approvals since 2011, including the recent approvals of the PD-1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda).

The combination of trametinib (Mekinist) and dabrafenib (Tafinlar) improved overall survival (OS) compared with vemurafenib alone in patients with unresectable (stage IIIC) or metastatic (stage IV) BRAFV600E/K mutation-positive cutaneous melanoma.